Advertisement

Recurrent Meningitis

  • Ibtihal Benhsaien
  • Ahmed Aziz Bousfiha
  • Fatima Ailal
Chapter

Abstract

Complement deficiencies are present in up to 20% of patients with disseminated Neisseria infections

Anatomical problems are the leading cause for recurrent meningitis

Meningitis occurs in approximately 40% of individuals with late component complement deficiencies showing a 1000–10,000 fold increase compared to general population

There are no specific treatments for complement deficiencies. Infection prevention and appropriate treatment of infections is key in the care of patients with these deficiencies.

Vaccination is highly recommended against influenza, pneumococcal and meningococcal diseases. Immunization against Neisseria meningitides with a tetravalent conjugate vaccine is strongly recommended

Quadrivalent meningococcal polysaccharide–protein conjugate vaccines against meningococcal serogroups A, C, W, and Y appear to be superior to tetravalent vaccines for long-term individual protection

Keywords

Quadrivalent meningococcal vaccine Complement deficiency C4 deficiency 

References

  1. 1.
    Rosain J, Ngo S, Bordereau P, Poulain N, Roncelin S, Vieira Martins P, Dragon-Durey MA, Fremeaux-Bacchi V. Complement deficiencies and human diseases. Ann Biol Clin. 2014;72(3):271–80.Google Scholar
  2. 2.
    Grumach AS, Kirschfink M. Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach. Mol Immunol. 2014;61(2):110–7.CrossRefGoogle Scholar
  3. 3.
    Tebruegge M, Curtis N. Epidemiology, etiology, pathogenesis, and diagnosis of recurrent bacterial meningitis. Clin Microbiol Rev. 2008;21(3):519–37.CrossRefGoogle Scholar
  4. 4.
    Seelen MA, Roos A, Wieslander J, Mollnes TE, Sjoholm AG, Wurzner R, Loos M, Tedesco F, Sim RB, Garred P, Alexopoulos E, Turner MW, Daha MR. Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Methods. 2005;296(1–2):187–98.CrossRefGoogle Scholar
  5. 5.
    Bousfiha A, Jeddane L, Picard C, Ailal F, Bobby Gaspar H, Al-Herz W, Chatila T, Crow YJ, Cunningham-Rundles C, Etzioni A, Franco JL, Holland SM, Klein C, Morio T, Ochs HD, Oksenhendler E, Puck J, Tang MLK, Tangye SG, Torgerson TR, Casanova JL, Sullivan KE. The 2017 IUIS phenotypic classification for primary immunodeficiencies. J Clin Immunol. 2018;38(1):129–43.CrossRefGoogle Scholar
  6. 6.
    Cohen R, Levy C. Meningococcal vaccines: from polysaccharide to conjugate vaccines. Arch Pediatr. 2012;19(Suppl 2):S61–4.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Ibtihal Benhsaien
    • 1
    • 2
  • Ahmed Aziz Bousfiha
    • 1
    • 2
  • Fatima Ailal
    • 1
    • 2
  1. 1.Clinical Immunology Unit, Harouchi Children Hospital, Ibn Rochd Hospital UniversityCasablancaMorocco
  2. 2.Clinical Immunology, Autoimmunity and Autoinflammatory Laboratory (LICIA)CasablancaMorocco

Personalised recommendations